VTYX - Ventyx Biosciences autoimmune/autoinflammatory candidate meets phase 1 goals

• VTX2735, a candidate from Ventyx Biosciences ( NASDAQ: VTYX ) for autoimmune and autoinflammatory conditions, met safety, tolerability, and pharmacokinetics goals in a phase 1 trial.
• The trial evaluated single ascending dose and multiple ascending doses. Drug-related adverse events were mild.
• There was strong pharmacodynamic activity based on plasma samples fromsubjects.  Also, VTX2735 demonstrated strong dose-related suppression of the induced pro-inflammatory cytokine IL-1? release relative to placebo.
• VTX2735 is an oral, selective inhibitor of NLRP3. When NLRP3 is activated, it initiates an immune response, stimulating the production of inflammatory cytokines (such as IL-1? and IL-18) as well as as cell death called pyroptosis.
• The company is planning a phase 2 trial in cryopyrin-associated periodic syndrome, a rare autoinflammatory condition.

For further details see: